88 related articles for article (PubMed ID: 10474832)
21. Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice.
Walker VE; Gorelick NJ; Andrews JL; Craft TR; deBoer JG; Glickman BW; Skopek TR
Cancer Res; 1996 Oct; 56(20):4654-61. PubMed ID: 8840980
[TBL] [Abstract][Full Text] [Related]
22. Is MutaMouse insensitive to clastogens?
Lynch AM; Mahabir AG; Bradford A; Brockhurst K; van Benthem J; van Steeg H; Rees RW
Mutat Res; 2008 Apr; 652(2):145-50. PubMed ID: 18387845
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a plasmid-based transgenic mouse model for detecting in vivo mutations.
Dollé ME; Martus HJ; Gossen JA; Boerrigter ME; Vijg J
Mutagenesis; 1996 Jan; 11(1):111-8. PubMed ID: 8671725
[TBL] [Abstract][Full Text] [Related]
24. Organ distinctive mutagenicity in MutaMouse after short-term exposure to PhIP.
Lynch AM; Gooderham NJ; Boobis AR
Mutagenesis; 1996 Sep; 11(5):505-9. PubMed ID: 8921513
[TBL] [Abstract][Full Text] [Related]
25. Genetic analysis of PHIP intestinal mutations in MutaMouse.
Lynch AM; Gooderham NJ; Davies DS; Boobis AR
Mutagenesis; 1998 Nov; 13(6):601-5. PubMed ID: 9862191
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutation in the mammary gland: influence of time and estrus.
Sun B; Shima N; Heddle JA
Mutat Res; 1999 Jun; 427(1):11-9. PubMed ID: 10354497
[TBL] [Abstract][Full Text] [Related]
27. Transmission of mutations in the lacI transgene to the offspring of ENU-treated Big Blue male mice.
Barnett LB; Tyl RW; Shane BS; Shelby MD; Lewis SE
Environ Mol Mutagen; 2002; 40(4):251-7. PubMed ID: 12489115
[TBL] [Abstract][Full Text] [Related]
28. Mutation spectrum of o-aminoazotoluene in the cII gene of lambda/lacZ transgenic mice (MutaMouse).
Kohara A; Suzuki T; Honma M; Hirano N; Ohsawa K; Ohwada T; Hayashi M
Mutat Res; 2001 Apr; 491(1-2):211-20. PubMed ID: 11287313
[TBL] [Abstract][Full Text] [Related]
29. Evidence for in vivo non-mutagenicity of the carcinogen hydrazine sulfate in target tissues of lacZ transgenic mice.
Douglas GR; Gingerich JD; Soper LM
Carcinogenesis; 1995 Apr; 16(4):801-4. PubMed ID: 7728958
[TBL] [Abstract][Full Text] [Related]
30. An assay for loss of heterozygosity in vivo at the Dlb-1 locus.
Vomiero-Highton G; Heddle JA
Mutagenesis; 1995 Sep; 10(5):381-4. PubMed ID: 8544749
[TBL] [Abstract][Full Text] [Related]
31. Mutation induction by N-propyl-N-nitrosourea in eight MutaMouse organs.
Hara T; Hirano K; Hirano N; Tamura H; Sui H; Shibuya T; Hyogo A; Hirashio T; Tokai H; Yamashita Y; Kura K
Mutat Res; 1999 Aug; 444(2):297-307. PubMed ID: 10521670
[TBL] [Abstract][Full Text] [Related]
32. The accumulation and persistence of somatic mutations in vivo.
Tao KS; Heddle JA
Mutagenesis; 1994 May; 9(3):187-91. PubMed ID: 7934958
[TBL] [Abstract][Full Text] [Related]
33. Tissue-specific metabolic activation and mutagenicity of 3-nitrobenzanthrone in MutaMouse.
Chen G; Gingerich J; Soper L; Douglas GR; White PA
Environ Mol Mutagen; 2008 Oct; 49(8):602-13. PubMed ID: 18613036
[TBL] [Abstract][Full Text] [Related]
34. Statistical analysis of lacZ mutant frequency data from MutaMouse mutagenicity assays.
Fung KY; Douglas GR; Krewski D
Mutagenesis; 1998 May; 13(3):249-55. PubMed ID: 9643583
[TBL] [Abstract][Full Text] [Related]
35. Enhanced somatic mutation rates induced in stem cells of mice by low chronic exposure to ethylnitrosourea.
Shaver-Walker PM; Urlando C; Tao KS; Zhang XB; Heddle JA
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11470-4. PubMed ID: 8524785
[TBL] [Abstract][Full Text] [Related]
36. No evidence for transgenerational genomic instability in the F1 or F2 descendants of Muta™Mouse males exposed to N-ethyl-N-nitrosourea.
O'Brien JM; Williams A; Gingerich J; Douglas GR; Marchetti F; Yauk CL
Mutat Res; 2013; 741-742():11-7. PubMed ID: 23499255
[TBL] [Abstract][Full Text] [Related]
37. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
38. In vivo mutagenicity and hepatocarcinogenicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in bitransgenic c-myc/lambda lacZ mice.
Ryu DY; Pratt VS; Davis CD; Schut HA; Snyderwine EG
Cancer Res; 1999 Jun; 59(11):2587-92. PubMed ID: 10363978
[TBL] [Abstract][Full Text] [Related]
39. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea.
Allay E; Veigl M; Gerson SL
Oncogene; 1999 Jun; 18(25):3783-7. PubMed ID: 10391687
[TBL] [Abstract][Full Text] [Related]
40. Lack of mutagenicity of levofloxacin in lacZ transgenic mice.
Itoh S; Miura M; Shimada H
Mutagenesis; 1998 Jan; 13(1):51-5. PubMed ID: 9491394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
